Duchenne Muscular Dystrophy

Entering a new chapter in the treatment of Duchenne

Duchenne muscular dystrophy (DMD) is one of the most serious genetic diseases in children worldwide, an X-linked pediatric neuromuscular disorder with an occurrence of 1 in 3,500–5,000 males. See a presentation by Dr. Wendy Chung, medical geneticist at Columbia University, New York, to learn some key clinical aspects of DMD, including pathophysiology, clinical course, and a comparison of promising gene therapies in development.

CK-MM: a newborn screening marker for Duchenne muscular dystrophy

With a host of life-altering therapies in development for Duchenne muscular dystrophy, it is vital to identify boys affected with DMD using newborn screening. Early detection enables earlier treatment and better outcomes. See a presentation by Professor Mei Baker of the University of Wisconsin Department of Pediatrics, where she discusses the performance of PerkinElmer’s CK-MM assay, used for first-tier screening for DMD.

Building infrastructure for Duchenne newborn screening pilot

In a New York pilot study that can serve as a model for future efforts in the USA and worldwide, over 17,000 newborns have been screened for DMD using PerkinElmer’s CK-MM assay. “We strongly believe that newborn screening for Duchenne would enable treatment using mutation-specific, muscle-directed therapies before muscle damage progresses,” says Dr. Amy Brower of the American College of Medical Genetics and Genomics. See her presentation to learn more.

Watch Webinar Now

Required only for US and Canada